Extraintestinal complications of inflammatory bowel diseases

Česká verzia

Authors: Vít Navrátil ¹; Silvia Cveková ¹; Peter Slodička ¹; Květoslava Aiglová ¹; Barbora Pipek ^1,2,3; Přemysl Falt ¹
Authors place of work: II. interní klinika – gastroenterologická a geriatrická LF UP a FN Olomouc ¹; Centrum péče o zažívací trakt, Nemocnice AGEL Ostrava Vítkovice, a. s. ²; Ostravská univerzita, Lékařská fakulta, Ostrava ³
Published in the journal: Vnitř Lék 2021; 67(2): 92-96
Category: Main Topic

Summary

Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC). Those are chronic gastrointestinal disorders of inflammatory nature and not fully known etiology. As a result of their immune-mediated mechanism and complex impact on the whole organism other organs than gastrointestinal system may be affected in many ways. These extraintestinal manifestations (EIM) and complications may severely deteriorate prognosis of the patient, cause his morbidity and worsen the quality of life. While classical extraintestinal manifestations, such as enteropathic arthropathy, skin or eye involvement or primary sclerosing cholangitis, share common immunopathological mechanism with IBD, whole range of other disorders may result from various anatomical or metabolic abnormalities caused by IBD or its treatment. This review focus on the most common extraintestinal complications, such as anaemia, metabolic bone disease, biliary and urolithiasis, which we meet in our daily clinical practice.

Keywords:

anemia – inflammatory bowel disease – lithiasis – metabolic bone disease – extraintestinal complications

Zdroje

1. Ferreira SDC, Oliveira BBMD, Morsoletto AM et al. Extraintestinal manifestations of inflammatory bowel disease: Clinical aspects and pathogenesis. J Gastroenterol Dig Dis 2018; 3(1): 4–11.

2. Vavricka SR, Schoepfer A, Scharl M et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis 2015; 21(8): 1982–1992.

3. Zbořil V a kol. Idiopatické střevní záněty. Praha: Mladá fronta, 2018.

4. Hrdlička L, Kohout P, Liberda M et al. Doporučený postup pro diagnostiku a léčbu anémie u IBD. Gastroent Hepatol 2012; 66(4): 280–285.

5. Harpavat M, Keljo DJ, Regueiro MD. Metabolic bone disease in inflammatory bowel disease. J Clin Gastroenterol. 2004 Mar; 38(3): 218–224.

6. Fojtík P, Urban O, Falt P, Novosad P. Výživa a sekundární osteoporóza, Interní Med. 2009; 11(12): 561–568.

7. Conly JM, Stein K, Worobetz L et al. The contribution of vitamin K2 (menaquinones), produced by the intestinal microflora to human nutritional requirements for vitamin K. Am J Gastroenterol 1994; 89: 915–923.

8. Buchman, A. Metabolic Bone Disease and Inflammatory Bowel Disease, American Journal of Gastroenterology: June 2007 – Volume 102 - Issue - p 49-55.

9. Ambruzs JM, Larsen CP. Renal Manifestations of Inflammatory Bowel Disease. Rheum Dis Clin North Am 2018; 44(4): 699–714.

10. Teplan V, Honsová E, Lukáš M Renální onemocnění pacientů s idiopatickými střevními záněty. Gastroent Hepatol 2020; 74(3): 256–266.

11. Corica D, Romano C. Renal Involvement in Inflammatory Bowel Diseases. J Crohns Colitis 2016; 10(2): 226–235.

12. Katsanos K, Tsianos EV. The kidneys in inflammatory bowel disease. Ann Gastroenterol 2002; 15(1): 41–52.

13. Maconi G, Bolzacchini E, Dell‘Era A et al. Portal vein thrombosis in inflammatory bowel diseases: A single‑ center case series, Journal of Crohn’s and Colitis, 2012; 6(3): 362–367.

14. Sinagra E, Aragona E, Romano C et. al. The Role of Portal Vein Thrombosis in the Clinical Course of Inflammatory Bowel Diseases: Report on Three Cases and Review of the Literature, Gastroenterology Research and Practice, 2012, 7 pages.

15. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006; 12(30): 4819–4831.

16. Chen CH, Lin CL, Kao CH. Association between Inflammatory Bowel Disease and Cholelithiasis: A Nationwide Population‑Based Cohort Study. Int J Environ Res Public Health. 2018 Mar 14; 15(3): 513.

17. Duboc H, Rajca S, Rainteau D et al. Connecting dysbiosis, bile‑acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013; 62: 531–539.

18. Fousekis FS, Theopistos VI, Katsanos KH et al. Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. Gastroenterology Res. 2018; 11(2): 83–94.

19. Sturdik I, Krajcovicova A, Jalali Y et al. Pathophysiology and Risk Factors for Cholelithiasis in Patients with Crohn’s Disease, Physiol. 68 (2): S173–S1821.

20. Bessissow T, Le NH, Rollet K, et al. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel, DiS. 2016; 22 (8): 1937–1944.

21. Obici L, Merlini G. Amyloidosis in autoinflammatory syndromes. Autoimmun Rev., 2012; 12(1): 14–17.

22. Sharma P, Aguilar R, Siddiqui OA et al. Secondary systemic amyloidosis in inflammatory bowel disease: a nationwide analysis. Ann Gastroenterol. 2017; 30(5): 504–511.

23. Sattianayagam PT, Gillmore JD, Pinney JH et al. Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci 2013; 58(6): 1689–1697.